Evaluating the therapeutic potential of EXL01 in a diversified and complementary set of indications for which F. prausnitzii's signal has been reported.
A two-part, partially double-blind, randomized phase 1 maintenance trial evaluating EXL01 for the maintenance of steroid-induced remission in patients with mild-to-moderate Crohn’s disease, is currently recruiting.
EXL02 is a pre-clinical Live Biotherapeutic candidate leveraging the properties of another gut bacteria, with a focus on its ability to activate the AhR-pathway.
EXL03
EXL03 is a preclinical recombinant protein candidate mimicking the properties of natural enzymes, in particular its ability to activate the Kynurenine pathway.
We would be glad to discuss partnership opportunities with you
